Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re VL.

J Natl Cancer Inst. 2019 Nov 5. pii: djz214. doi: 10.1093/jnci/djz214. [Epub ahead of print]

PMID:
31687755
2.

Grade 1 Acute on Chronic Liver Failure is a Predictor for Subsequent Grade 3 Failure.

Mahmud N, Sundaram V, Kaplan DE, Taddei TH, Goldberg DS.

Hepatology. 2019 Nov 2. doi: 10.1002/hep.31012. [Epub ahead of print]

PMID:
31677284
3.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V  III.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 1. doi: 10.1158/1055-9965.EPI-19-0503. [Epub ahead of print]

PMID:
31575557
4.
5.

Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K.

Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.

PMID:
31356807
6.

Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma.

Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS.

Transplantation. 2019 Jun 24. doi: 10.1097/TP.0000000000002816. [Epub ahead of print]

PMID:
31283688
7.

Reply.

Mahmud N, Kaplan DE, Taddei TH, Goldberg DS.

Hepatology. 2019 Dec;70(6):2236-2238. doi: 10.1002/hep.30835. No abstract available.

PMID:
31243784
8.

Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Mahmud N, John B, Taddei TH, Goldberg DS.

Clin Transplant. 2019 Jul;33(7):e13634. doi: 10.1111/ctr.13634. Epub 2019 Jun 25.

PMID:
31177570
9.

Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis.

Serper M, Kaplan DE, Shults J, Reese PP, Beste LA, Taddei TH, Werner RM.

Hepatology. 2019 Dec;70(6):2062-2074. doi: 10.1002/hep.30779. Epub 2019 Jun 26.

PMID:
31107967
10.
11.

Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B.

Fox RK, Taddei TH, Kaplan DE.

JAMA Intern Med. 2019 May 1;179(5):640-641. doi: 10.1001/jamainternmed.2018.8314. No abstract available.

PMID:
30882884
12.

Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis.

Kaplan DE, Serper MA, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH; VOCAL Study Group.

Gastroenterology. 2019 May;156(6):1693-1706.e12. doi: 10.1053/j.gastro.2019.01.026. Epub 2019 Jan 18.

13.

Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis.

Mahmud N, Kaplan DE, Taddei TH, Goldberg DS.

Hepatology. 2019 May;69(5):2150-2163. doi: 10.1002/hep.30494. Epub 2019 Mar 20.

PMID:
30615211
14.

Hepatocellular Carcinoma Outcome Is Predicted by Expression of Neuronal Calcium Sensor 1.

Schuette D, Moore LM, Robert ME, Taddei TH, Ehrlich BE.

Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1091-1100. doi: 10.1158/1055-9965.EPI-18-0167. Epub 2018 May 22.

15.

Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.

Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH.

J Vasc Interv Radiol. 2018 Apr;29(4):540-549.e4. doi: 10.1016/j.jvir.2017.11.033. Epub 2018 Feb 22.

16.

Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.

Kaplan DE, Mehta R, D'Addeo K, Valderrama A, Taddei TH; Sorafenib for Hepatocellular carcinomA in VEterans (SHAVE) Study Investigators.

Medicine (Baltimore). 2018 Jan;97(4):e9757. doi: 10.1097/MD.0000000000009757.

17.

Palliative care in decompensated cirrhosis: A review.

Langberg KM, Kapo JM, Taddei TH.

Liver Int. 2018 May;38(5):768-775. doi: 10.1111/liv.13620. Epub 2018 Jan 15. Review.

PMID:
29112338
18.

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.

Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE.

J Clin Oncol. 2017 Nov 1;35(31):3575-3581. doi: 10.1200/JCO.2017.73.8245. Epub 2017 Sep 5.

19.

Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.

Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D'Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH; VOCAL Study Group.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):106-114.e5. doi: 10.1016/j.cgh.2017.07.024. Epub 2017 Jul 26.

20.

Pursuing a Gastroenterology Fellowship as a Foreign Medical Graduate.

Njei B, Taddei TH.

Dig Dis Sci. 2017 Aug;62(8):1852-1854. doi: 10.1007/s10620-017-4624-9. No abstract available.

PMID:
28555326
21.

Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES.

Butt AA, Ren Y, Lo Re V 3rd, Taddei TH, Kaplan DE.

Clin Infect Dis. 2017 Jul 1;65(1):64-72. doi: 10.1093/cid/cix224.

PMID:
28369305
22.

Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination.

Vilarinho S, Erson-Omay EZ, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH.

J Hepatol. 2017 Jul;67(1):186-191. doi: 10.1016/j.jhep.2017.03.009. Epub 2017 Mar 18.

23.

Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.

Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group.

Gastroenterology. 2017 Jun;152(8):1954-1964. doi: 10.1053/j.gastro.2017.02.040. Epub 2017 Mar 7.

24.

HIV, Aging, and Viral Coinfections: Taking the Long View.

Taddei TH, Lo Re V 3rd, Justice AC.

Curr HIV/AIDS Rep. 2016 Oct;13(5):269-78. doi: 10.1007/s11904-016-0327-7. Review.

PMID:
27614654
25.

Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man.

Ooka K, Onyiuke I, Zhang X, Taddei TH.

BMJ Case Rep. 2016 Sep 2;2016. pii: bcr2016216649. doi: 10.1136/bcr-2016-216649.

26.

Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.

Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama A, Kaplan DE.

Hepatology. 2017 Mar;65(3):864-874. doi: 10.1002/hep.28765. Epub 2016 Oct 5.

PMID:
27531119
27.

Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis.

Langberg KM, Taddei TH.

Hepatology. 2016 Oct;64(4):1014-6. doi: 10.1002/hep.28717. Epub 2016 Aug 5. No abstract available.

PMID:
27388118
28.

Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma?

Taddei TH.

Hepatology. 2016 Apr;63(4):1078-9. doi: 10.1002/hep.28452. Epub 2016 Mar 1. No abstract available.

PMID:
26764271
29.

Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.

Kaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Knott A, Pedrosa M, Pocha C, Mehta R, Duggal M, Skanderson M, Valderrama A, Taddei TH; VOCAL Study Group.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2333-41.e1-6. doi: 10.1016/j.cgh.2015.07.010. Epub 2015 Jul 15.

30.

Emphysematous Cholecystitis Resulting in Secondary Biliary Cirrhosis: A Rare Complication of Endoscopic Retrograde Cholangiopancreatography.

Bari K, Aslanian HR, Pollak J, Reiner E, Salem RR, Taddei TH, Emre SH, Jamidar PA.

ACG Case Rep J. 2013 Oct 8;1(1):51-4. doi: 10.14309/crj.2013.18. eCollection 2013 Oct.

31.

New frontier in liver cancer treatment: oncolytic viral therapy.

Vilarinho S, Taddei TH.

Hepatology. 2014 Jan;59(1):343-6. doi: 10.1002/hep.26605. Epub 2013 Nov 15. No abstract available.

32.

Journal of Clinical Gastroenterology. Introduction.

Taddei TH, Nathanson MH.

J Clin Gastroenterol. 2013 Jul;47 Suppl:S1. doi: 10.1097/MCG.0b013e3182936b7e. No abstract available.

PMID:
23751799
33.

A multidisciplinary approach: group dynamics.

Taddei TH.

J Clin Gastroenterol. 2013 Jul;47 Suppl:S27-9. doi: 10.1097/MCG.0b013e31829331de.

PMID:
23632364
34.

When should a hepatitis C-positive ESRD patient receive a renal transplant?

Kulkarni S, Taddei TH.

Semin Dial. 2011 Jul-Aug;24(4):438-9. doi: 10.1111/j.1525-139X.2011.00898.x. Epub 2011 Jul 29. No abstract available.

PMID:
21801216
35.

Systemic therapy in hepatocellular carcinoma.

Wrzesinski SH, Taddei TH, Strazzabosco M.

Clin Liver Dis. 2011 May;15(2):423-41, vii-x. doi: 10.1016/j.cld.2011.03.002. Review.

36.

Necrotizing pancreatitis complicated by fistula and upper gastrointestinal hemorrhage.

Sahakian AB, Krishnamoorthy S, Taddei TH.

Clin Gastroenterol Hepatol. 2011 Jul;9(7):e66-7. doi: 10.1016/j.cgh.2011.01.022. Epub 2011 Feb 4. No abstract available.

PMID:
21296188
37.

High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease.

Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK.

J Inherit Metab Dis. 2010 Jun;33(3):291-300. doi: 10.1007/s10545-010-9070-1. Epub 2010 Mar 31.

38.

The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK.

Am J Hematol. 2009 Apr;84(4):208-14. doi: 10.1002/ajh.21362.

39.
40.

Impact of body mass index on graft failure and overall survival following liver transplant.

Rustgi VK, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH.

Clin Transplant. 2004 Dec;18(6):634-7.

PMID:
15516235

Supplemental Content

Loading ...
Support Center